Theravance Biopharma (TBPH) Cash from Financing Activities (2013 - 2026)
Theravance Biopharma (TBPH) reported Cash from Financing Activities of -$5.6 million for Q1 2026, down 553.04% year-over-year from $1.2 million in Q1 2025, and down 274.04% quarter-over-quarter from -$1.5 million in Q4 2025.
Theravance Biopharma (TBPH) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Cash from Financing Activities data on file, last reported at -$5.6 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$5.6 million, down 553.04% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.0 million (down 387.52% YoY), and the FY2025 annual result was -$3.2 million, down 30.08% from the prior year.
- Cash from Financing Activities slipped to -$5.6 million in Q1 2026 per TBPH's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $140000.0 in Q2 2022 and troughed at -$701.8 million in Q3 2022.
- A 5-year average of -$55.8 million and a median of -$1.5 million in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities tumbled 57728.57% in 2023, then surged 99.95% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$35.5 million in 2022, then climbed by 13.71% to -$30.6 million in 2023, then soared by 98.81% to -$365000.0 in 2024, then slumped by 308.49% to -$1.5 million in 2025, then sank by 274.04% to -$5.6 million in 2026.
- Business Quant data shows TBPH's Cash from Financing Activities at -$5.6 million in Q1 2026, -$1.5 million in Q4 2025, and -$400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 85,464.43 |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | -5.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.58 Mn |
| Mar 31, 2026 | -5.58 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Dec 31, 2025 | -1.49 Mn |
| Sep 30, 2025 | -400,000.00 |
| Sep 30, 2025 | -400,000.00 |
| Jun 30, 2025 | -503,000.00 |
| Jun 30, 2025 | -503,000.00 |
| Mar 31, 2025 | -854,000.00 |
| Mar 31, 2025 | -854,000.00 |
| Dec 31, 2024 | -365,000.00 |
| Dec 31, 2024 | -365,000.00 |
| Sep 30, 2024 | -372,000.00 |
| Sep 30, 2024 | -372,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Mar 31, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.72 Mn |
| Dec 31, 2023 | -30.61 Mn |
| Dec 31, 2023 | -30.61 Mn |